Trillium Therapeutics Inc (TRIL)

[NY1972]

Other studies focused on the genetic characterization of tumors to discriminate responders from non-responders to immune checkpoint therapy and found that responses to immunotherapy were higher in patients with highly mutated cancers such as melanoma and NSCLC (Rizvi et al., 2015; Snyder et al., 2014). The proposed theory is that the mutational load of each cancer directly correlates with the likelihood of expressing novel mutations that are recognized by the immune system, the so called neoantigens.

http://www.discoverymedicine.com/Claudia-Voena/2016/02/advances-in-cancer-immunology-and-cancer-immunotherapy/